Safety Criteria for Polysomnography in Patients with Cellulitis
Patients with cellulitis can safely undergo polysomnography (PSG) as long as they do not have systemic signs of infection (SIRS), altered mental status, or hemodynamic instability. 1, 2
Clinical Decision Algorithm
Step 1: Assess Cellulitis Severity and Systemic Involvement
Proceed with PSG if the patient has:
- Mild cellulitis without systemic signs (no fever, normal vital signs, localized erythema only)
- Stable vital signs (no tachycardia, normal blood pressure, temperature <38.5°C)
- Normal mental status
- No evidence of SIRS (absence of fever, tachycardia, tachypnea, leukocytosis)
Defer PSG if the patient has:
- Fever, tachycardia, confusion, hypotension, or leukocytosis 1
- Concern for deeper or necrotizing infection 1, 2
- Severe systemic features requiring hospitalization 1
- Poor adherence to therapy or severely immunocompromised state 2
Step 2: Evaluate Treatment Status
The IDSA guidelines clearly delineate hospitalization criteria for cellulitis. Outpatient therapy is appropriate for patients without SIRS, altered mental status, or hemodynamic instability 1, 2. If the patient meets outpatient criteria and cellulitis is being appropriately treated, PSG can proceed.
Key safety considerations:
- Ensure the patient is on appropriate antimicrobial therapy (typically an agent active against streptococci for uncomplicated cellulitis) 1
- Verify at least 24-48 hours of clinical stability on antibiotics before scheduling PSG
- Confirm the affected area is elevated and predisposing factors are being addressed 1, 2
Step 3: Address Practical Concerns
Equipment and positioning:
- Cellulitis location matters: lower extremity cellulitis should not interfere with standard PSG monitoring equipment
- Ensure electrode placement avoids areas of active infection
- Maintain elevation of the affected limb during the study when feasible 1, 2
Infection control:
- Standard precautions are sufficient for uncomplicated cellulitis (no special isolation required)
- Ensure proper cleaning of equipment between patients per facility protocols
Step 4: Monitor for Complications
While adverse events during PSG are uncommon (1 event per 623 studies), cardiac events and falls are most common 3. In cellulitis patients, be particularly vigilant for:
- Worsening pain or erythema during the study
- Development of fever or systemic symptoms
- Fall risk if lower extremity cellulitis affects mobility
Common Pitfalls to Avoid
Do not delay necessary PSG indefinitely: Once cellulitis is clinically stable on appropriate antibiotics without systemic signs, there is no contraindication to proceeding with sleep studies
Do not confuse local inflammation with systemic infection: Localized erythema, warmth, and tenderness without fever or altered vital signs does not preclude PSG 1
Do not overlook predisposing factors: Examine interdigital toe spaces for tinea pedis or maceration, as treating these reduces recurrence risk 1, 2
Special Circumstances
If cellulitis is associated with:
- Penetrating trauma, injection drug use, or purulent drainage: Ensure MRSA coverage is included in antibiotic regimen before PSG 1, 2
- Severe immunocompromise: Consider deferring PSG until infection is fully resolved and patient is clinically stable
- Recurrent cellulitis: Address underlying risk factors (edema, obesity, venous insufficiency, toe web abnormalities) before scheduling 1, 2
The key principle is straightforward: if the patient is stable enough for outpatient management of their cellulitis, they are stable enough for PSG. The presence of cellulitis alone is not a contraindication—only systemic involvement or clinical instability warrants postponement.